Anticancer activity of Hedyotis corymbosa nanoliposomes targeting estrogen receptor-alpha in breast cancer cells: In silico and in vitro studies
Clicks: 75
ID: 278953
2024
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Emerging Content
22.2
/100
75 views
22 readers
AI Quality Assessment
Not analyzed
Readership in this journal
EmergingRanked #57 of 60 articles by views in journal of pharmacy and pharmacognosy research
Most read
Least read
Bar heights use a square-root scale.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Context: Breast cancer expresses high levels of the estrogen receptor alpha (ER-α).
Aims: To investigate the potential anticancer activity of nanoliposome Hedyotis corymbosa in breast cancer cells by specifically targeting the ER-α through a combination of in silico and in vitro studies.
Methods: This study used molecular docking to analyze the interaction between ER-α and active compounds from H. corymbosa. In vitro studies, the H. corymbosa extract was converted into nanoliposomes. The nanoliposomes' characteristics were examined, combined with tamoxifen, and applied to breast cancer cell cultures. Viability, proliferation, and ER-α expression were assessed, and statistical analysis was performed (p<0.05).
Results: The findings show that H. corymbosa compounds, especially rutin, inhibit ER -α binding and act as a substrate for P-glycoprotein. Extract H. corymbosa selectively decreases viability in breast cancer cells (T47D) compared to non-cancerous cells (NIH3T3). Combining extracts with tamoxifen at 10 mg/mL enhances treatment efficacy. The combined treatment is effective for up to 72 h, reducing T47D breast cancer cell proliferation. Nanoliposomes derived from extract exhibit favorable characteristics, including a spherical shape, uniform size distribution, and stability. Using these nanoliposomes at 100 μg/mL with tamoxifen significantly reduces ER-α expression (p<0.05) without affecting cell viability.
Conclusions: Compounds from H. corymbosa, especially rutin, inhibit ER-α binding. H. corymbosa nanoliposomes are stable for drug delivery. Combining tamoxifen with nanoliposomes at 100 μg/mL reduces ER-alpha expression. This shows potential for breast cancer treatment, but validation through further research and clinical trials is necessary.
Abstract Quality Issue:
This abstract appears to be incomplete or contains metadata (99 words).
Try re-searching for a better abstract.
| Reference Key |
permana2024anticancerjournal
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Permana, S. |
| Journal | journal of pharmacy and pharmacognosy research |
| Year | 2024 |
| DOI |
10.56499/jppres23.1783_12.2.303
|
| URL | |
| Keywords | Keywords not found |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.